Skip to main content

Day: March 28, 2023

Itaú Corpbanca Files Material Event Notice to announce Dividend Distribution Proposal

SANTIAGO, Chile, March 28, 2023 (GLOBE NEWSWIRE) — ITAÚ CORPBANCA (NYSE: ITCB; SSE: ITAUCORP) In an ordinary board meeting held today, the Board of Directors of Itaú Corpbanca (the “Bank”) resolved to propose to the Annual General Shareholders’ Meeting, to be held on April 20, 2023, the distribution of 30% of the distributable net income for the fiscal year 2022, which represents an aggregate amount of $130,123,237,338, payable to the holders of the 973,517,871,202 validly issued shares of the Bank. If approved dividend distribution of $0.1336629158920 per share would be payable. In addition, it will be proposed to the Shareholders Meeting that the remaining 70% of the profits to be retained of the Bank’s Board of Directors The full Material Event Notice is available on the company’s investor relations website at ir.itau.cl. Investor...

Continue reading

Clover Announces Corporate Updates and Full Year 2022 Financial Results

— Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in 2023 with continued growth thereafter — — Clover’s COVID-19 vaccine now listed in 24 provinces and municipalities in China (representing >80% population coverage) and well-positioned to be a major player in upcoming vaccination campaigns; anticipated to receive emergency use authorization (EUA) and sign a bilateral supply agreement in at least one additional country in H1 2023 — — AdimFlu-S (QIS) commercial production ongoing and on-track for H2 2023 launch as the only imported quadrivalent seasonal influenza vaccine approved in mainland China in a stable and growing market — — On track to build a leading respiratory vaccine franchise; currently...

Continue reading

Dundee Corporation Returns to Profit in 2022 and Announces Fourth Quarter and Year-End Results

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announced its financial results for the three months and year ended December 31, 2022. All currency amounts in this press release are in Canadian dollars except as otherwise indicated. FOURTH QUARTER AND YEAR-END 2022 RESULTSReported net income from investments for the fourth quarter of 2022 of $39.9 million (2021 – $12.1 million). For the year ended December 31, 2022, the Corporation reported net income from investments of $53.6 million (2021 – loss of $38.5 million).Reported net earnings attributable to owners of the Corporation for the fourth quarter of 2022 of $26.0 million (2021 – loss of $13.6 million), or earnings of $0.28 per share, before the effect of any dilutive securities (2021 – loss of $0.17 per share)....

Continue reading

Equus Announces Fourh Quarter Net Asset Value

HOUSTON, March 28, 2023 (GLOBE NEWSWIRE) — Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of December 31, 2022, of $35.2 million. Net asset value per share decreased to $2.61 as of December 31, 2022, from $2.68 as of September 30, 2022. Comparative data is summarized below (in thousands, except per share amounts):As of the Quarter Ended 12/31/2022 9/30/2022 6/30/2022 3/31/2022 12/31/2021Net assets $35,237 $36,230 $37,155 $37,435 $36,365Shares outstanding   13,518   13,518   13,518   13,518   13,518Net assets per share $2.61 $2.68 $2.75 $2.77 $2.69The following was the principal contributor to the increase in fair value of the Company’s portfolio holdings in 2022:Increase in the Value of Equus Energy. During 2022, the fair value of Equus Energy, LLC, increased from $13.0 million...

Continue reading

Nobel Withdraws From Option to Acquire the Algarrobo Copper Project in Chile

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX–V: NBLC; OTC: NBTRF) (the “Company” or “Nobel”) has decided to withdraw from its option to acquire the Algarrobo project (the “Project”) in Chile. According to Vern Arseneau, COO of Nobel, “After completing an extensive drill campaign on multiple target areas and reviewing the data from the Project, we have concluded that although there remains some potential for a deep porphyry on the property, alteration assemblages suggest it is likely too deep and in an area with a very thick dune cover and as such unlikely to be an economically viable target.” Qualified Person The scientific and technical information in this news release has been reviewed and approved by Mr. David Gower, P.Geo., as defined by National Instrument 43-101 of the Canadian Securities Administrators. About...

Continue reading

DLC Releases Annual 2022 Results; Achieves Annual Funded Volumes of $70.6 Billion

VANCOUVER, British Columbia, March 28, 2023 (GLOBE NEWSWIRE) — Dominion Lending Centres Inc. (TSX:DLCG) (“DLCG” or the “Corporation”) is pleased to report its financial results for the three months and year ended December 31, 2022 (“Q4-2022” and “annual”, respectively). For complete information, readers should refer to the annual audited consolidated financial statements, management discussion and analysis (“MD&A”) and annual information form (“AIF”) which are dated March 28, 2023 and available on SEDAR at www.sedar.com and on the Corporation’s website at www.dlcg.ca. All amounts are presented in Canadian dollars unless otherwise stated. Reference herein to the Dominion Lending Centres Group of Companies (the “DLC Group” or “Core Business Operations”) includes the Corporation and its three main subsidiaries, MCC Mortgage Centres...

Continue reading

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

GreenLight’s RTP greenhouse facility in North Carolina GreenLight’s RTP greenhouse facility in North CarolinaTwo agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical strategy to accelerate development of its next-generation Covid vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidate Presented promising preclinical immune response data for Shingles vaccine candidate, first program in partnership with Serum Institute of India Private LimitedBOSTON, March 28, 2023 (GLOBE NEWSWIRE) — GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest...

Continue reading

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

LONDON, March 28, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. “In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ASTRAEUS study of alvelestat in severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) were highly encouraging, and formed the basis for productive discussions with the regulatory agencies in both the U.S. and EU, culminating in our recent announcement of the details of our potential pivotal study design,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. “We believe our...

Continue reading

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

– Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond – – Roche sponsoring randomized, multi-national phase 1b/2 trial of novel triple combination therapy in first-line liver cancer, leveraging safety profile of masked, anti-CTLA-4 SAFEbody® ADG126 – – Sanofi and Exelixis collaborations present multi-billion dollar opportunity for non-dilutive funding via milestones and royalties – – Cash balance of US$143.8 million supports streamlined operations into 2025 – SAN DIEGO and SUZHOU, China, March 28, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company...

Continue reading

Healthcare Triangle Reports Fourth Quarter and Full Year 2022 Results

30% annual revenue growth to $46 million led by software services and successful integration of Devcool acquisition PLEASANTON, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (Nasdaq: HCTI), a leading provider of cloud and digital transformation, managed services, and data analytics solutions for the healthcare and life sciences industry, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial ResultsRevenue: Total revenue was $11.3 million, representing growth of 23% compared to the fourth quarter of 2021. Revenue from the Software Services and Platform Services segments increased by 82% and 55%, respectively, partially offset by a 31% decrease in Managed Services and Support.GAAP loss from operations: GAAP loss from operations was $4.9...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.